Cablevision's support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.

Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Lustgarten Foundation firmly believes that increasing funds for pancreatic cancer research is the surest path to improved patient care and eventually, to a cure. To date, we have committed nearly $90 million to providing the best and brightest minds with the resources to pursue the study and eradication of the disease.

2012 Research Grants

Harnessing the metabolic vulnerability of pancreatic cancer cells to develop novel therapies
Dafna Bar-Sagi, Ph.D. - New York University School of Medicine

Treatment of pancreatic cancer by tumor-penetrating delivery of siRNA
William C. Hahn, M.D., Ph.D.– Harvard Medical School Dana Farber Cancer Institute 
Sangeeta Bhatia, M.D., Ph.D.–The David H. Koch Institute for Integrative Cancer Research at MIT

Development of Small Molecule Inhibitors of the Pancreatic Cancer Metabolism
Alec Kimmelman, M.D., Ph.D. –Dana Farber Cancer Institute
Lewis Cantley, Ph.D. – Beth Israel Deaconess Medical Institute
Luke Lairson, Ph.D. – Scripps Research Institute

Development of a multi-parametric magnetic resonance imaging approach for early pancreatic cancer diagnosis
Hadassa Degani, Ph.D.- Weizmann Institute

Dissection of Cancer-Induced Cachexia and Muscle Wasting
Douglas T. Fearon, Ph.D. - Cambridge Research Institute UK

Mechanisms Driving Interstitial Fluid Pressures in PDA
Sunil Hingorani, M.D., Ph.D. – Fred Hutchinson Cancer Research Center

Combination therapies targeting K-ras pathways
Tyler Jacks, Ph.D. – The David H. Koch Institute for Integrative Cancer Research at MIT

Immunotherapy Clinical Trial
Carl June, M.D. and Gregory Beatty, Ph.D. – Abramson Family Cancer Research Institute
at the University of Pennsylvania

High Risk Registry for BRCA mutation carrier-pancreatic ductal adenocarcinoma
David Kelsen, M.D. – Memorial Sloan Kettering Cancer Center

Dynamics of Development and Maintenance of Tumor-Stroma Interactions in Pancreatic Cancer
Mikala Egeblad, Ph.D. – Cold Spring Harbor Laboratory
Scott Lowe, Ph.D. – Memorial Sloan Kettering Cancer Center

Novel TSPO PET Ligands to Image Pancreatic Cancer
H. Charles Manning, Ph.D.– Vanderbilt University

Analysis of the effects of the intestinal microbiome in pancreatic cancer
George Miller, M.D. - New York University School of Medicine

Testing Promising Drug Combinations in BRCA1 and BRCA2 Patients
Eileen O'reilly, M.D. And David Kelsen, M.D. - Memorial Sloan Kettering Cancer Center in collaboration with Dana Farber Cancer Institute, Sha'are Zedek Medical Center and Rabin Medical Center, Israel

Focused Ultrasound Technologies for Diagnosis, Monitoring, and Treatment of Pancreatic Cancer
Ken Olive, Ph.D. – New York-Presbyterian Hospital/Colombia University Medical Center

Novel oncolytic vaccinia strains for targeted pancreatic cancer therapy
Stephen Thorne, Ph.D.- University of Pittsburgh Cancer Institute

Lustgarten Foundation Pancreatic Cancer Laboratory
David Tuveson, M.D., Ph.D. – Cold Spring Harbor Laboratory

Magnetic resonance imaging of pancreatic cancer with contrast agents targeted by activatable cell-penetrating peptides (ACPPD)
Roger Y. Tsien, Ph.D. – University of California, San Diego

Detection of early pancreatic neoplasia
Bert Vogelstein, M.D. – The Johns Hopkins University School of Medicine

Targeting stromal collagen in pancreatic cancer
Daniel Von Hoff, M.D. – Translational Genomics Research Institute
Stand Up To Cancer Dream Team Translational Cancer Research Grant
Daniel Von Hoff, M.D., FACP - Translational Genomics Research Institute
Craig Thompson, M.D.,- Memorial Sloan Kettering Cancer Center

Role of neurons in the development and progression of pancreatic cancer
Timothy C. Wang, M.D. - Columbia University Medical Center

Defining the pancreatic cancer kinome landscape
Jen Jen Yeh, M.D. – University of North Carolina School of Medicine

Building a Map of Pancreatic Cancer Cachexia and Muscle Wasting
Teresa A. Zimmers, Ph.D. - Thomas Jefferson University Kimmel Cancer Center

Elizabeth Jaffee, M.D., Johns Hopkins Medical Institutions
“As a result of Lustgarten Foundation funding, we were able to produce enough vaccine to test our potential therapy in pancreatic cancer patients. Without this funding, we would not have been able to conduct this trial.”
-  Elizabeth Jaffee, M.D., Johns Hopkins Medical Institutions

Lustgarten Foundation funds pancreatic cancer research through Bridge Project.

The Lustgarten Foundation has made a generous gift of $650,000 to the Bridge Project, an unparalleled collaboration between Dana-Farber/Harvard Cancer Center (DF/HCC) and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). (see page 6)

2015 website development and design sponsored by Celgene

1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303